Encompass Health Corporation
EHC · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.72 | 0.63 | -0.64 | 0.28 |
| FCF Yield | 3.91% | 4.03% | 2.05% | 3.20% |
| EV / EBITDA | 9.99 | 9.27 | 10.19 | 9.81 |
| Quality | ||||
| ROIC | 11.80% | 10.42% | 9.51% | 10.42% |
| Gross Margin | 46.01% | 19.44% | 95.35% | 95.91% |
| Cash Conversion Ratio | 1.67 | 2.35 | 1.93 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.31% | 6.14% | 6.83% | -4.47% |
| Free Cash Flow Growth | 34.59% | 119.97% | -26.06% | -44.49% |
| Safety | ||||
| Net Debt / EBITDA | 2.22 | 2.79 | 3.40 | 3.96 |
| Interest Coverage | 6.29 | 5.10 | 3.57 | 5.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 6.40 | 3.22 |
| Cash Conversion Cycle | 19.16 | 30.45 | -137.90 | -84.37 |